Tazobactam is a pharmaceutical agent that inhibits the action of bacterial β-lactamases. It is commonly used as its sodium salt, tazobactam sodium. The drug is added to certain antibiotics to make them less susceptible to antimicrobial resistance in bacteria. Tazobactam is commonly given with the β-lactam antibiotic piperacillin, which is used for infections caused by Pseudomonas aeruginosa.
Effect
Pharmacodynamics
Tazobactam broadens the spectrum of piperacillin by making it effective against organisms that express beta-lactamase and would normally degrade it. It does this by irreversibly inhibiting beta-lactamase enzymes.
Pharmacokinetics
Maximum plasma concentrations occur immediately after intravenous infusion. Tazobactam is approximately 30% bound to plasma proteins. Tazobactam and its metabolite are excreted primarily by the kidneys, with approximately 80% of the administered dose excreted as unchanged drug. The plasma half-life is approximately 1 hour.
Aktories, Förstermann, Hofmann, Starke: Allgemeine und spezielle Pharmakologie und Toxikologie, Elsvier, 2017
Editorial principles
All information used for the content comes from verified sources (recognised institutions, experts, studies by renowned universities). We attach great importance to the qualification of the authors and the scientific background of the information. Thus, we ensure that our research is based on scientific findings.
Markus Falkenstätter, BSc Author
Markus Falkenstätter is a writer on pharmaceutical topics in Medikamio's medical editorial team. He is in the last semester of his pharmacy studies at the University of Vienna and loves scientific work in the field of natural sciences.
Mag. pharm. Stefanie Lehenauer Lector
Stefanie Lehenauer has been a freelance writer for Medikamio since 2020 and studied pharmacy at the University of Vienna. She works as a pharmacist in Vienna and her passion is herbal medicines and their effects.
The content of this page is an automated and high-quality translation from DeepL. You can find the original content in German here.
